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Coronaviruses
Coronaviruses (CoVs), a genus of the Coronaviridae
family, are positive-strand RNA viruses with the
largest viral genome of all RNA viruses (27–32
kb).1 The genomic RNA is capped, polyadenylated
and covered with nucleocapsid proteins. The virus
is enveloped and carries large spike glycoproteins.
All CoVs have a common genome organization,
in which the replicase gene encompasses the 5
two-thirds of the genome and is comprised of two
overlapping open reading frames (ORFs), ORF1a
and ORF1b. The structural gene region, which
covers the 3 third of the genome, encodes the
canonical set of structural protein genes in the
order 5 - spike (S) - envelope (E) - membrane (M)
and nucleocapsid (N) - 3 (Figure 1). Some group II
CoVs carry an additional structural protein that
encodes a hemagglutinin esterase. The gene is 
located between the ORF1b and S gene. Expres-
sion of the non-structural replicase proteins is
mediated by translation of the genomic RNA that
gives rise to the biosynthesis of two large poly-
proteins, pp1a (encoded by ORF1a) and pp1ab
(encoded by ORF1a and ORF1b), which is facili-
tated by a ribosomal frameshift at the ORF1a/1b
junction. In contrast, the structural proteins are
translated from subgenomic mRNAs. These sub-
genomic mRNAs are the result of discontinuous
transcription, a hallmark of CoV gene expression.
The structural gene region also harbors several
ORFs that are interspersed along the structural
protein coding genes. The number and location
of these accessory ORFs vary between the CoV
species.
In animals, CoV infections can lead to a vari-
ety of syndromes, e.g. bronchitis, gastroenteritis,
progressive demyelinating encephalitis, diarrhea,
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HCoV-NL63 and HCoV-229E are two of the four human coronaviruses that circulate worldwide. These
two viruses are unique in their relationship towards each other. Phylogenetically, the viruses are more
closely related to each other than to any other human coronavirus, yet they only share 65% sequence
identity. Moreover, the viruses use different receptors to enter their target cell. HCoV-NL63 is associated
with croup in children, whereas all signs suggest that the virus probably causes the common cold in
healthy adults. HCoV-229E is a proven common cold virus in healthy adults, so it is probable that both
viruses induce comparable symptoms in adults, even though their mode of infection differs. Here, we
present an overview of the current knowledge on both human coronaviruses, focusing on similarities and
differences. [J Formos Med Assoc 2009;108(4):270–279]
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peritonitis and respiratory tract disease.1 The first
reports on human CoVs (HCoV) appeared in the
mid-1960s. The human viruses were isolated from
persons with the common cold, and two species
were detected: HCoV-229E and HCoV-OC43.2,3
Almost 40 years later, a CoV was identified as the
causative agent of the severe acute respiratory
syndrome (SARS).4,5 A highly effective global
public health response prevented further spread
of this virus, and as a result, SARS-CoV was erad-
icated from the human population. Soon there-
after, it became clear that there are more HCoVs.
HCoV-NL63 was identified in 2004 and HCoV-
HKU1 in 2005.6,7 Both viruses are not emerging
viruses like SARS-CoV but were previously un-
identified. In fact, infections caused by these
viruses are as common and widespread as HCoV-
229E and HCoV-OC43 infections.8
The SARS outbreak intensified research on
the unknown animal CoVs. As many as 16 new
animal CoV species have been identified in the
last 3 years.9–16 There are currently 29 complete
reference genome sequences available in GenBank
of the various viruses, and three phylogenetically
distinct groups exist (Figure 2).17,18 HCoV-229E
and HCoV-NL63 belong to the group 1 CoVs, to-
gether with various CoVs isolated from pigs, cats
and bats. As shown in Figure 2, HCoV-229E and
HCoV-NL63 are the only two human viruses that
have a relatively close relationship. HCoV-OC43
is a group 2 virus and clusters tightly with bovine,
porcine and equine CoVs. HCoV-HKU1 is not part
of that cluster, although the virus clearly belongs
to the group 2 CoVs. SARS-CoV is of animal origin,
with civet cat SARS-CoV and bat SARS-CoV as very
close relatives.19
Discovery of Group 1 CoVs
The first described CoV of group 1 was porcine
transmissible gastroenteritis virus (TGEV), which
was isolated in 1946 from pigs suffering from
gastroenteritis.20 Almost two decades later, one
research group located in the UK identified a hu-
man respiratory tract pathogen from nasal wash-
ings of persons with the common cold.2 This novel
pathogen, HCoV-229E, was later characterized
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Figure 1. Schematic representation of the genomic organization of group 1 coronaviruses (CoVs). Group 1B CoVs HCoV-
229E (NC002645), HCoV-NL63 (NC005831), porcine epidemic diarrhea virus (PEDV; NC003436), bat coronavirus 1A
(Bt-CoV 1A; NC010437), Bt-CoV 1B (NC010436), Bt-CoV 512/2005 (NC009657), Bt-CoV HKU2 (NC009988) and 
Bt-CoV HKU8 (NC010438), and group 1A CoVs porcine transmissible gastroenteritis virus (TGEV; NC002306) and feline
infectious peritonitis virus (FIPV; NC007025) genome organization. The open reading frames (ORFs) are denoted as
replicase 1A (ORF1a), replicase 1B (ORF1b), S, E, M, N and accessory genes (ORFx).
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morphologically by electron microscopy and
compared with the already-well-known avian in-
fectious bronchitis virus.21 The viruses exhibited
a typical crown-like appearance (from Latin co-
rona). During the following years, another group 1
member, canine coronavirus, was isolated from
sentry dogs with diarrhea and mild gastroenteri-
tis.22 Similar clinical symptoms were later observed
in pigs during a diarrheal outbreak in 1978 on
four separate swine breeding farms.23 The recov-
ered pathogen, now known as porcine epidemic
diarrhea virus (PEDV), was first mistyped as a
Figure 2. Phylogenetic tree of 29 full-genome coronavirus (CoV) reference strains. The full-genome CoV reference se-
quences were aligned with ClustalX v2.09.17 Phylogenetic analysis was conducted with the neighbor-joining method,
Kimura 2-parameter distances and a bootstrap of 1000 replicates, using MEGA version 4.01.18 Bootstrap values below
75 are not shown. The five human CoV species are highlighted by a rectangle. The viruses are denoted as bovine coro-
navirus (BCoV), porcine hemagglutinating encephalomyelitis virus (PHEV), equine coronavirus (EqCoV), mouse hepatitis
virus (MHV), severe acute respiratory syndrome CoV (SARS-CoV), Turkey coronavirus (TCoV), avian infectious bronchi-
tis virus (IBV), porcine epidemic diarrhea virus (PEDV), bat CoV (Bt-CoV), porcine transmissible gastroenteritis virus
(TGEV), feline infectious peritonitis virus (FIPV), and beluga whale coronavirus (SW1-CoV).
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member of the rotavirus family, yet it soon be-
came clear that the virus shared the morphologi-
cal characteristics of CoV but was serologically
distinct from TGEV.23 Two cat-associated CoV
species were identified in 1981. Feline enteric
coronavirus and feline infectious peritonitis virus
(FIPV) shared serological characteristics, but dif-
fered in clinical outcome.24 In 1986, another
porcine CoV was isolated, porcine respiratory
coronavirus, a close relative of TGEV.25 Hereafter,
no new group 1 members were discovered for
more than 15 years.
In 2004, we isolated HCoV-NL63 from a 
7-month-old child with bronchiolitis.6 Shortly
thereafter, Fouchier et al independently described
the same virus from a clinical sample collected 
in 1988.26 In 2005, it became clear that several
bat species can harbor CoVs that belong to 
group 1.10,14,16 Most of these viruses cluster with
HCoV-229E, HCoV-NL63 and PEDV, although
none of them is a very close relative to any of
these viruses.
There are notable differences in the genome
composition that divides the group 1 viruses
into two separate branches, named 1A and 1B
(Figure 1). All group 1A members contain several
short accessory protein-coding genes between the
S and E genes and one or two accessory protein
genes on the 3’ side of the N gene. In contrast, all
group 1B members carry only one accessory pro-
tein gene, between the S and E genes, with the ex-
ception of some bat CoVs. Three bat CoVs carry
an additional ORF at the 3’-side of the N gene.
The function of the accessory proteins from the
group 1 CoVs is unknown. Reverse genetic analyses
of FIPV and extensive cell culture adaptation of
PEDV, TGEV and HCoV-229E suggest that they
are not required for in vitro virus replication.27–31
Moreover, deletion of FIPV, PEDV and TGEV ac-
cessory genes results in attenuation of the virus,
which indicates that the group 1 accessory pro-
teins represent pathogenicity factors.27–30
The discovery timeline of the group 1 CoVs il-
lustrates that this group has grown only recently
into a more mature form in which its members
can infect a diversity of mammalian hosts. It is
not unlikely that additional members will be
identified in the near future.
Evolution and Variability of HCoV-229E
and HCoV-NL63
HCoV-229E was the first HCoV to be fully 
sequenced;32 however, it is striking that the se-
quence information of circulating strains is very
poor. Only one study has described the vari-
ability of the S and N genes over time, which 
suggests that genetic drift shapes HCoV-229E
evolution.33 Fortunately, the sequence informa-
tion allows calculation of the evolution rate of
the virus. With this evolutionary rate, the time to
the most common recent ancestor of HCoV-
NL63 and HCoV-229E could be calculated.34 As
many as 1000 years ago, the viruses evolved from
a common ancestor.34
For HCoV-NL63, many more sequences of
circulating strains are now available. Four full
genomes have been sequenced, and 312 sequences
of other regions are available in GenBank (com-
pared to 123 for HCoV-229E). The full-length
HCoV-NL63 sequences have shown that two types
of viruses exist, but recombination between
HCoV-NL63 strains occurs frequently.34
Unfortunately, it is unknown whether differ-
ent types of HCoV-229E strains exist and recom-
bination occurs, since only the first full-length
sequence of the laboratory-adapted strain VR-
740 is available thus far.32 Full-length sequences
of clinical isolates are urgently needed to address
this question. The limitation of having just one
laboratory-adapted strain sequence is exempli-
fied by our analysis of the ORF4 region of HCoV-
229E.31 The laboratory-adapted VR-740 strain
contains ORF4a and ORF4b genes, and it was 
assumed that clinical isolates would follow the
same gene order. We have sequenced the region
from several clinical samples and revealed that
HCoV-229E in patients always contains an intact
ORF4 gene that encodes one putative ORF4 acces-
sory protein, whereas laboratory-adapted strains
are very prone to mutations in this region.31
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Cell Tropism of HCoV-229E and 
HCoV-NL63
The S glycoproteins of HCoV-229E and HCoV-
NL63 are both class I fusion proteins that medi-
ate infection of target cells.35,36 The proteins share
56% amino acid identity, but do not use the same
receptor.37 The receptor-recognition regions within
S are, for both viruses, not well-defined linear
binding sites.38 For HCoV-NL63, the region be-
tween amino acids 476 to 616 is important for
binding, whereas for HCoV-229E, amino acids 417
to 547 are involved in receptor recognition.39,40
HCoV-229E utilizes CD13 (also known as ami-
nopeptidase N) as a receptor, whereas HCoV-NL63
uses angiotensin-converting enzyme 2 (ACE2) for
cellular entry.41–43
CD13 is a zinc-binding metalloprotease that
is ubiquitously expressed in various cell types,
including small intestinal and renal tubular epi-
thelial cells, the granulocytic and monocytic line-
age, synaptic membranes from the central nervous
system, and respiratory epithelial cells.44–46 CD13
functions in digestion, angiogenesis and synap-
tic activity, and cleaves peptides bound to major
histocompatibility complex molecules of antigen-
presenting cells.46 ACE2 belongs to the same pro-
tease family as CD13, and the protein is expressed
in testicular, renal, cardiovascular, gastrointestinal
and airway tissue.47 Both metalloproteases are
involved in the renin–angiotensin system, which
regulates blood pressure. ACE2 plays a role in 
vasodilatation by C-terminal cleavage of angio-
tensin II into angiotensin 1–7, and angiotensin I
into angiotensin 1–9, whereas CD13 functions
at another level by N-terminal cleavage of angio-
tensin III into angiotensin I, and angiotensin IV
into angiotensin 4–8.48
Besides HCoV-229E, CD13 is used by PEDV,
TGEV and FIPV to enter the cell,49–52 whereas
HCoV-NL63 is the sole group 1 virus that uses
ACE2. Only SARS-CoV uses the same protein for
entry.53 It has been suggested that SARS-CoV
pathogenicity is related to the downregulation of
ACE2 upon infection.54 ACE2 protects against
lung damage and the lack of ACE2 on the cell
surface may account for the damage during in-
fection.54 Whether HCoV-NL63 induces a similar
downregulation during infection is unknown.
HCoV-229E can be cultured on various types
of cells derived from the human nervous system,
cells of granulocytic and monocytic lineage, airway
tract cells and hepatocytes.44,45,55,56 HCoV-NL63
in vitro replication can be achieved by culturing
upon monkey-kidney-derived cell lines, tertiary
monkey kidney cells and hepatocytes.6,26,43,57
On pseudostratified human primary lung epithe-
lial cell cultures, CD13 and ACE2 proteins are 
expressed on the apical surface.45,58 The release
of newly produced HCoV-229E viral particles 
exhibits the same polarization as the receptor, and
therefore, apical release, whereas for HCoV-NL63,
this is still unknown.45 Unfortunately, to date, no
permissive animal models have been reported
that can be utilized as in vivo models to further
characterize HCoV-229E- or HCoV-NL63-induced
pathogenicity.59–61
Prevalence of HCoV-NL63 and 
HCoV-229E
An accumulating number of reports has revealed
that HCoV-229E and HCoV-NL63 infections
occur without gender, age or geographic bound-
aries.8,62–65 All children encounter their first
HCoV-229E and HCoV-NL63 infection during
early childhood.43,66,67 In most children, these
infections do not lead to severe clinical symp-
toms, but for some, the severity of the upper or
lower respiratory tract infections can require hos-
pitalization. HCoV-NL63 and HCoV-229E infec-
tions can account for 5% of all acute respiratory
infections in the hospital, especially during the
winter.68,69 Very often, these severe infections are
accompanied by a second respiratory virus infec-
tion.70 At a later age, reinfection with the viruses
occurs, but only in frail persons does the infec-
tion require hospital admission.6,64,65 Studies with
HCoV-229E infection of volunteers have shown
that reinfection with common cold symptoms
occurs when the level of antibodies directed
against the virus is low.71 The decrease in titers of
HCoV-229E antibodies is observed as soon as 
1 year after infection, which indicates that every
individual probably encounters numerous infec-
tions by HCoV-229E during a lifetime. Whether
reinfection of HCoV-NL63 in healthy adults 
occurs is still unknown.
Disease Association of HCoV-NL63 and
HCoV-229E
Until 1989, clinical infection trials with HCoV-
229E in healthy volunteers were performed by re-
searchers at the Medical Research Council (MRC)
in Salisbury, UK. HCoV-229E was administered
nasally to volunteers.72 Among the infected vol-
unteers, 50% developed the common cold. The
observed symptoms included malaise, headache,
nasal discharge, chills, cough and sore throat. One
fifth of the volunteers developed fever. The incu-
bation period ranged from 2 to 5 days, with a mean
of just over 3 days. The duration of symptoms that
were induced by HCoV-229E varied between 2
and 18 days, with a mean of 7 days. During the
trials, researchers also noticed the high daily
amount of disposable handkerchiefs used. From
this, it was concluded that nasal discharge is one
of the main symptoms of HCoV-229E infection.
The number of handkerchiefs used ranged from
8 to 120, with a mean of 23 per day, a high num-
ber compared to other common cold viruses, such
as rhinoviruses. In addition, the mean incubation
period of HCoV-229E was significant longer than
that of rhinoviruses, whereas the duration of the
illness was somewhat shorter. Similar symptoms
were observed with nine different HCoV-229E
strains, thus, no indications that various strains
of HCoV-229E induce different symptoms.73
The most frequently observed clinical manifes-
tations in HCoV-NL63-infected patients are fever,
cough, coryza, sore throat, bronchiolitis, bronchi-
tis, pneumonia and croup.8 As mentioned above,
HCoV-NL63 infections in the hospital are frequent-
ly accompanied by infection with other respiratory
viruses. Therefore, association of HCoV-NL63
with a certain disease remains difficult to establish.
We investigated a large group of 949 children with
lower respiratory tract infections and found that,
among those infected with HCoV-NL63, a large
percentage had croup (24%).70 Focusing only on
single HCoV-NL63 infections revealed a very strong
association (43%, p<0.0001). A second study con-
firmed this finding. Five hundred and thirty-nine
Taiwanese children were tested and HCoV-NL63
was the most common pathogen (14.7%) in chil-
dren who had croup.74 Also, two Korean studies
observed the association of HCoV-NL63 with
croup.62,75 One study found three (50%) cases of
croup among HCoV-NL63-infected children, and
the other found 64.2% of croup among 14 chil-
dren with HCoV-NL63 infection. We hypothesize
that HCoV-NL63 is responsible for croup, since in
most studies, no other pathogen has been detected.
Still, it cannot be ruled out that laryngotracheitis
facilitates HCoV-NL63 replication, but the virus
is not involved in causing the disease. Whether
HCoV-229E is involved in croup is unknown.
HCoV-229E testing of the above-mentioned 949
children (tested previously for HCoV-NL63) will
shed more light on this matter. Therefore, it is of
interest to determine the prevalence of HCoV-
229E infection among children with croup.
There has been one study that has linked
HCoV-NL63 infection to Kawasaki disease,76 one
of the most common forms of childhood vas-
culitis.77 However, no subsequent study has been
able to confirm this association.78–82 HCoV-229E
has been suggested as the causative agent of mul-
tiple sclerosis.83–86 Some research groups have
found a higher frequency of HCoV-229E in the
brains of patients with multiple sclerosis com-
pared to a control group. However, the high fre-
quency might have been influenced by the
increased susceptibility of these patients, as a 
result of damage to the blood–brain barrier.
Therapy
Common cold virus infections have a large 
impact on the economy because of the reduced
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productivity of the working population. There-
fore, effective viral treatment against the common
cold may limit this economic impact. Addition-
ally, effective treatment can modulate severe res-
piratory disease among children or elderly and
immunocompromised patients. Currently, there
are no treatments available for any of the HCoVs,
including HCoV-NL63 and HCoV-229E. However,
some candidate drugs have been investigated
and might provide options for treatment in the
future.
The viral replication cycle of HCoV-229E and
HCoV-NL63 can be tackled theoretically by syn-
thetic or natural antiviral compounds at various
stages, including receptor binding, membrane
fusion, transcription, RNA biosynthesis and post-
translational processing. For HCoV-NL63 and
HCoV-229E, there are no inhibitory neutralizing
monoclonal antibodies available. However, 
HCoV-NL63 replication can be inhibited in vitro
by pooled intravenous immunoglobulins from
healthy adult donors, which probably contain
neutralizing antibodies.87 Whether this also 
relates to HCoV-229E remains to be investigated,
although it is not unlikely since many healthy
adults carry antibodies directed against HCoV-
229E.88 Treatment with intravenous immunoglob-
ulins is beneficial in numerous (auto)immune
diseases, such as multiple sclerosis, but also severe
respiratory diseases and Kawasaki disease.89
Type I interferon (IFN-α and IFN-β) modu-
late the viral permissiveness and replication effi-
ciency by toggling infected and neighboring cells
into their antiviral state.90 For HCoV-229E, it is
known that IFN-α exhibits a potent antiviral ac-
tivity towards HCoV-229E in vitro and in vivo.91,92
However, prolonged intranasal administration of
IFN-α to HCoV-229E-infected volunteers gave
rise to blood-stained nasal discharge, a side effect
which is perhaps worse than the common cold
that is caused by HCoV-229E.92
Other novel means to inhibit viral replication
are RNA interference87,93 and broad-spectrum
protease inhibitors.87,91 Nevertheless, the in vivo
efficacy and safety of these inhibitors remain to
be established.
Concluding Remarks
To date, there is a lot known about HCoV-229E
and HCoV-NL63, but there are several areas of
research that are underrepresented. For instance,
the sequence information on HCoV-229E is very
limited, and an animal model for both HCoVs is
urgently needed. Furthermore, the implication
of the receptor usage of HCoV-229E and HCoV-
NL63 on the renin–angiotensin system remains
to be established. Future research will hopefully
reveal the mechanism by which these viruses cause
disease. Understanding of the pathogenesis may
eventually lead to a simple, non-hazardous treat-
ment that can be used with acute respiratory in-
fections not only in the hospital, but also at home
to cure common colds.
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